Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: A one-year, randomized, double-blind, multicenter study versus placebo

Osteoarthritis and Cartilage

Volumn 12, Issue 4, 2004, Pages 269-276

  Uebelhart, Daniel ^a,b   Malaise, Michel ^c   Marcolongo, Roberto ^d   DeVathairell, Florent ^e   Piperno, Muriel ^f   Mailleux, Elisabeth ^c   Fioravanti, Antonella ^d   Matoso, Luis ^g   Vignon, Eric ^f  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d Institute of Rheumatology   (Italy)

^e INSERM   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g NONE

Author keywords

Chondroitin sulfate; Joint space narrowing; Knee osteoarthritis; Lequesne's algo functional index

Indexed keywords

CHONDROITIN SULFATE; PARACETAMOL; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; EPIGASTRIC PAIN; FEMALE; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; JOINT CAVITY; KNEE; KNEE OSTEOARTHRITIS; KNEE RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZATION; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; VISUAL ANALOG SCALE; WALKING; WEIGHT BEARING;

EID: 1842635731     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2004.01.004     Document Type: Article

References (37)

1. Lewis S, Crossman M, Flannelly J, Belcher C, Doherty M, Bayliss MT, et al. Chondroitin sulphation patterns in synovial fluid in osteoarthritis subsets. Ann Rheum Dis 1999;58:441-5.
2. Rouvinez de Rossi E, Roth M, Tajana E, Uebelhart D. Determination of chondroitin sulfates in human plasma by HPLC with UV detection of constituent OS, 4S and 6S disaccharides. Glycoconj J 1997;14:94.
3. Conte A, De Bernardi M, Palmieri L, Lualdi P, Mautone G, Ronca G. Metabolic fate of exogenous chondroitin sulfate in man. Arzneimittelforschung 1991;41: 768-72.
4. Ronca F, Palmieri L, Panicucci P, Ronca G. Antiinflammatory activity of chondroitin sulfate. Osteoarthritis Cart 1998;6(Suppl):A14-21.
5. Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf®) and its constituents in healthy male volunteers. Osteoarthritis Cart 2002;10:768-77.
6. Leeb BF, Schweitzer H, Montag K, Smolen JS. A meta analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000;27:205-11.
7. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: A systematic quality assessment and meta-analysis. JAMA 2000;283:1469-75.
8. Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996;23:1385-91.
9. Bourgeois P, Chales G, Dehais J, Delcambre B, Kuntz JL, Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3×400 mg/day vs placebo. Osteoarthritis Cart 1998;6(Suppl):A25-30.
10. Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cart 1998;6(Suppl): A31-6.
11. Mazières B, Combe B, Phan Van A, Tondut J, Grynfeltt M. Chondroitin sulfate in osteoarthritis of the knee: A prospective, double blind, placebo controlled multicenter clinical study. J Rheumatol 2001;28:173-81.
12. Uebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: A pilot study. Osteoarthritis Cart 1998;6(Suppl):A39-46.
13. Altman RD, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29:1039-49.
14. Altman RD. Criteria for the classification of osteoarthritis of the knee and hip. Scand J Rheumatol 1987;65:31-9.
15. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation-value in comparison with other assessment tests. Scand J Rheumatol 1987;0(Suppl): 6585-9.
16. Huskisson EC. Measurement of pain. J Rheumatol 1982;9:768-9.
17. Kellgren JH, Lawrence JJ. Radiologic assessment of osteoarthritis. Ann Rheum Res 1957;16:494-502.
18. Piperno M, Hellio le Graverand MP, Conrozier T, Bochu M, Mathieu P, Vignon E. Quantitative evaluation of joint space width in femorotibial osteoarthritis: Comparison of three radiographic views. Osteoarthritis Cart 1998;6:252-9.
19. Conrozier T, Tron AM, Mathieu P, Vignon E. Quantitative assessment of radiographic normal and osteoarthritic hip joint space. Osteoarthritis Cart 1995;3(Suppl):A81-7.
20. Vignon E, Conrozier T, Piperno M, Richard S, Carrillon Y, Fantino O. Radiographic assessment of hip and knee osteoarthritis. Recommendations: Recommended guidelines. Osteoarthritis Cart 1999;7: 434-6.
21. Conrozier T, Tron AM, Balblanc JC, Mathieu P, Piperno M, Fitoussi G, et al. Measurements of the hip joint space using computerized image analysis. Rev. Med (Engl edn) 1993;60(2):105-11.
22. Zeger S, Liang L. Longitudinal data analysis using generalized linear models. Biometrika 1986;73: 13-22.
23. May WL, Johnson WD. Generalized estimating equations for multivariate response with the variates having different distributions. J Biopharm Stat 1996; 6:139-53.
24. Alekseeva LI, Benevolenskaia LI, Nasonov EL, Chichasova NV, Kariakin AN. Structum (chondroitin sulfate) - a new agent for the treatment of osteoarthritis. Ter Arkh 1999;71:51-3.
25. Lequesne M. Symptomatic slow-acting drugs in osteoarthritis: a novel therapeutic concept? Rev Rhum (Engl edn) 1994;61:69-73.
26. Moskowitz RW. Chondroprotective agents. Do they already exist? Europ J Rheumatol Inflamm 1991; 11:121-5.
27. Lesquesne M, Brandt K, Bellamy N, Moskowitz R, Menkes CJ, Pelletier JP, et al. Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol 1994;21:S65-71.
28. Uebelhart D, Thonar EJ, Zhang J, Williams JM. Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cart 1998;6(Suppl):A6.
29. Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis Cart 1998;6(Suppl):A37-8.
30. Verbruggen G, Goemaere S, Veys EM. Systems to Assess the Progression of Finger Joint Osteoarthritis and the Effects of Disease Modifying Osteoarthritis Drugs. Clin Rheumatol 2002;21:231-43.
31. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomised, placebo-controlled clinical trial. Lancet 2001;357: 251-6.
32. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati L. Glucosamine sulfate use and delay of progression of knee osteoarthritis. A 3-year, randomized, placebo-controlled, double-blind study. Arch Int Med 2002;162:2113-23.
33. McAlindon TE. Glucosamine for osteoarthritis: Dawn of a new era?. Lancet 2001;357:247-8.
34. Mazières B, Loyau G, Menkès CJ, Valat JP, Dreiser RL, Charlot J, et al. La chondroitine sulfate dans le traitement de la gonarthrose et de la coxarthrose. Rev Rhum 1992;59:466-72.
35. Howell DS, Altman RD. Cartilage repair and conservation in osteoarthritis. A brief review of some experimental approaches to chondroprotection. Rheum Dis Clin North Am 1993; 19:713-24.
36. Danao-Camara T. Potential side effects of treatment with glucosamine and chondroitin. Arthritis Rheum 2000;43:2853.
37. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JW, et al. EULAR recommendations for the management of knee osteoarthritis: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000;59:936-44.